Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-10), Travere Therapeutics's 3-1 Month Momentum % is 26.25%.
The industry rank for Travere Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
TVTX's 3-1 Month Momentum % is ranked better than 82.85% of 1382
companies
in the Biotechnology industry
Industry Median: 1.21
vs TVTX: 26.25
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Travere Therapeutics 3-1 Month Momentum % Related Terms
TVTX vs ERAS, ORKA, COGT: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Travere Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Travere Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics (TVTX) has a 3-1 Month Momentum % of 26.25% as of Sep. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Travere Therapeutics and its competitors. According to the industry distribution chart, Travere Therapeutics ranks #237 out of 1382 companies in the Biotechnology industry, placing it in the top 17.1%.
Is Travere Therapeutics' 3-1 Month Momentum % too high?
Travere Therapeutics' current 3-1 Month Momentum % is 26.25%. The Biotechnology industry median 3-1 Month Momentum % is 1.21. Travere Therapeutics' value of 26.25% is 2069.4% above this industry median. Based on the distribution chart, Travere Therapeutics ranks #237 out of 1382 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' 3-1 Month Momentum % compare to ERAS and ORKA?
According to the Biotechnology industry distribution chart, Travere Therapeutics ranks #237 out of 1382 companies for 3-1 Month Momentum %. This places Travere Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.21. Travere Therapeutics' value of 26.25% is 2069.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.21, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Travere Therapeutics's current 3-1 Month Momentum % of 26.25% is 2069.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Travere Therapeutics and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Travere Therapeutics's current 3-1 Month Momentum % is 26.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $37.75, compared to a current price of $68.15 — trading 80.5% above its estimated fair value. The current 3-1 Month Momentum % is 26.25% and 2069.4% above the Biotechnology industry median of 1.21. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current 3-1 Month Momentum % is 26.25% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Travere Therapeutics (TVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued.
The current stock price of $68.15 is trading 80.5% above its estimated GF Value™ of $37.75.
GuruFocus considers Travere Therapeutics to be Significantly Overvalued.
Key valuation signals for TVTX:
3-1 Month Momentum %: 26.25%
GF Value™: $37.75 vs. price of $68.15 (80.5% above fair value)
Industry Position: 2069.4% above the Biotechnology median (#237 of 1382)
No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score
Get the complete analysis for TVTX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TVTX has been successfully added to your 
